Healthcare costs in US to shoot up following Trump tariff on Indian goods: Industry experts
New Delhi: Healthcare costs in the US will increase following the imposition of sweeping 25 per cent tariff plus an unspecified penalty on Indian goods, experts from pharmaceuticals and medical devices industry said on Thursday.
President Donald Trump on Wednesday announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1, plus an unspecified penalty for buying Russian crude oil and military equipment.
Profits for Indian pharmaceutical firms may decline and research and development may stagnate. However, for the medical devices sector as long as the gap between duty on China and India is over 15- 20 per cent, there are positive prospects for exports to the US, according to experts. "India isn't just a key supplier of generics to the US. We are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets," OmniActive Health Technologies Executive Chairman and MD Sanjaya Mariwala said. On the other hand, he said, "Back home, the profits for Indian pharmaceutical firms may decline, and R&D may stagnate, slowing down innovation and stalling new drug clearances."
AiMeD (Association of Indian Medical Device Industry) Forum Coordinator Rajiv Nath said, "Duties impact for Indian medical devices sector has to be seen from relative competitiveness - as long as duty gap between Chinese versus Indian is over 15- 20 per cent, we have positive prospects to export to USA and even put production lines in USA." Currently Indonesia and Vietnam have lower duties by 6 per cent. So for products made there they will possibly enjoy a price competitive advantage over India, he added. Stating that clarity will come after August 12 as then duties on Chinese goods will be clear, Nath said, "They were increased to over 50 per cent but temporarily reduced to 30 per cent. If post-August duties on Chinese medical devices revert to over 50 per cent and on Indian at 25 per cent, the export prospects versus China are in our favour..." He further said, "Suffice to say that whatever is the final duty that is finally announced on medical devices, if it's at least 15-20 per cent lower than applicable duty rates by US onto China then there is a strong opportunity for Indian medical devices to increase their exports to US market, if they are able to absorb the excessive high cost of regulatory approval of USFDA for market entry and find that these costs to export are sustainable over the years." However, he said, the government of India and manufacturers will need to work to improve India's competitiveness "so that we can offset the 6 per cent disadvantage over Indonesian and Vietnam competitors". Grant Thornton Bharat Partner and Tax Controversy Management Leader Manoj Mishra pointed out that the strong language used by President Trump and ongoing investigations into drug imports mean that the risk is not over yet. "Indian pharma companies should stay prepared for possible changes, especially if sector-specific duties are introduced later. That said, these tariffs are likely to be in place only for a short period, as both countries are expected to fast-track discussions for a Bilateral Trade Agreement. A balanced and stable trade deal will be key to protecting long-term interests of the sector," he noted. Similarly, Choice Broking Equity Research Analyst- Pharma Sector, Maitri Sheth said the US remains heavily reliant on India for its pharmaceutical needs, with about 50 per cent of generic drugs sourced from India. "Given the critical nature of healthcare and already elevated healthcare costs in the US, we view the likelihood of material near-term tariffs on pharma as low," Sheth added. While the headline risk persists, the structural dependence on Indian pharma and the cost sensitivity of the US healthcare system provide a strong case against aggressive tariff action on the sector, Sheth added.
Medical Technology Association of India (MTaI) Chairman Pavan Choudary said President Trump's is "troubling and seems economically shortsighted and strategically misguided".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
25 minutes ago
- India Today
May consider dividends to citizens: Trump on tariff revenue disbursal plans
The day the 25 per cent US tariffs on Indian imports came into effect, President Donald Trump said he might consider extending the "dividends" earned through the levies imposed on America's trade partners to its citizens, news agency Reuters reported on the Trump tariff tirade, while most European Union member countries and the UK were hit with 15 per cent levies, Japan with 10 per cent, and South Korea with just 5 per cent, India saw a 25 per cent blanket rate imposed on its products imported by the US. The US cited exponentially high tariffs by India on American products behind its Trump imposed a 35 per cent duty on many goods from Canada, 50 per cent on Brazil, 39 per cent on Switzerland and 20 per cent on Taiwan. Notably, Trump has signed a new executive order that imposes fresh import tariffs on goods from 69 countries and the European Union, which will come into effect on August per the order, Syria tops the list of highest tariffs at 41 per cent, followed by Laos and Myanmar at 40 per cent, and Iraq and Serbia at 35 per cent. Other countries such as Libya and Algeria will now face a 30 per cent China, against whom Trump once ordered tariffs as high as a whopping 145 per cent, is still negotiating with the US, with American officials saying that they are looking at an imminent trade deal. "But it is not 100 per cent done," US Treasury Secretary Scott Bessent told CNBC move is part of Trump's push for what he describes as more "fair and reciprocal" trade relationships. The White House said that some countries had failed to meet US expectations during trade talks, leading to these new Trump's tariff move and the deadline, global stock markets witnessed a slump as investors panicked, fearing a global supply chain disruption and the outcome of their talks with who had grown accustomed to Trump's frequent trade threats may now be facing a reality check, as broad tariffs on numerous countries have taken effect just as the deadline to negotiate trade agreements with the US passed without resolution.- EndsTune InMust Watch
&w=3840&q=100)
First Post
25 minutes ago
- First Post
Trump says he will 'release everything' related to Epstein Files amid reports of FBI redacting his name
Amid backlash, US President Donald Trump said that he will 'release everything' related to the Epstein Files. Trump's proclamation came after reports emerged that the FBI is redacting his name from the document before public release read more The clamour for releasing the Epstein files has overshadowed Trump's desperate bid to highlight the success of his first six months in power because it's not his rivals but his own base, which is up in arms. File image Hours after an explosive report revealed that the FBI 'redacted' US President Donald Trump's name from the Epstein Files, the American leader said that he wants to release 'everything" about the document revealing the ill-deeds of convicted sex offender and British financier Jeffrey Epstein. The proclamation from the president came amid growing backlash even among Republicans over his administration's reluctance to release the files. Trump's recent comment also marked a flip-flop from his previous assertion when he questioned the 'fascination" of his supporters with the case, dubbing it 'pretty boring stuff'. STORY CONTINUES BELOW THIS AD During an interview with Newsmax, the president also gave an insight into Deputy Attorney General Todd Blanche's conversation with the deceased sex offender's convicted accomplice, Ghislaine Maxwell, which went on for nine hours at a federal prison estate in Florida. 'I think [Blanche] probably wanted to know, you know, just to get a feeling of it, because we'd like to release everything, but we don't want people to get hurt that shouldn't be hurt,' Trump told Newsmax host Rob Finnerty. 'I want to release everything,' the president declared. 'I just don't want people to get hurt.' BREAKING: Trump says he wants to release 'everything' related to Epstein files… Wait… So Obama didn't 'write them' and it's not a 'hoax,' after the FBI redacted his name? — Brian Krassenstein (@krassenstein) August 2, 2025 'Todd went in, and I think he just wants to make sure that innocent people aren't hurt,' Trump added. However, the president maintained that he hasn't spoken with his deputy attorney general about Maxwell and doesn't know if there are plans to release a transcript of the interview. STORY CONTINUES BELOW THIS AD FBI reportedly redacted Trump's name from Epstein Files While the Trump administration often boasted about being 'transparent', an explosive report revealed that the president's name was redacted from documents surrounding the investigation into sex offender Jeffrey Epstein as the administration prepared for their potential public release. According to a report by Bloomberg, an investigator in the case reportedly blacked out Trump's name and the names of other high-profile figures, claiming that the information constituted an 'unwarranted invasion of privacy". In a previous report from The Wall Street Journal, it was mentioned that Attorney General Pam Bondi told the president that his name was in the files back in May. The matter garnered public anger in July after the Department of Justice and the FBI declined to release any additional documents. Public scrutiny of Trump's connections to Epstein and the financier's crimes and circumstances of his death intensified soon after the memo was released. In February this year, the White House handed over binders of largely publicly available Epstein-related documents to several far-right influencers in an apparent effort to prove that the administration was being transparent about the files. At that time, Bondi called the release of the documents the 'first phase' and went on to tell Fox News that other documents, including the so-called 'client list', are sitting on her desk for review. STORY CONTINUES BELOW THIS AD However, in the July memo, the FBI and DoJ backtracked and said that there is 'no basis to revisit the disclosure of those materials' despite demands from MAGA supporters and allies for full accountability. Hence, it remains unclear whether the Trump administration would ever release the full Epstein Files.
Time of India
25 minutes ago
- Time of India
Volvo shifts gears, to offer both EVs & ICE models in India
Volvo Cars will continue to introduce both electric and internal combustion engine (ICE) vehicles in India, pivoting its earlier strategy of going all-electric amid slow customer adoption of battery electric vehicles (BEVs). The Swedish luxury carmaker had last year said it will henceforth sell only electric vehicles in India in its bid to have an all-electric portfolio by the turn of the decade. Volvo's strategy mirrors those of other global car makers like Jaguar Land Rover, and Mercedes Benz who are revising plans to have an all-electric product range. Speaking to ET, Jyoti Malhotra, managing director at Volvo Cars India said, globally too while the company intends to go all electric, timelines have now been pushed beyond 2030. 'The adoption rate (of electric vehicles) is different in different countries. And even within the country (in India), it's different across states,' said Malhotra. He said government policies are crucial in deepening EV penetration in India, with states that have waived off road taxes seeing higher adoption rates among customers. 'We will continue to drive in electric cars and have a launch lined up later this year itself. But at the same time, we will continue to focus on ICE,' said Malhotra. EVs currently contribute about 25 per cent of Volvo's sales in India. The market for such eco-friendly luxury cars is however still small though it is growing, according to the company. 'About a year back, EVs had started losing steam. We are seeing some uptick in the segment in the last six months. But customer needs are different across regions,' said Malhotra. 'Home charging is extremely important for customer comfort when it comes to owning EVs. In cities, where there are high-rises, charging electric cars is challenging,' he said, adding Volvo is seeing stronger EV adoption in states like Kerala, Maharashtra, and Delhi where there are low-rises and state policies are conducive. He was speaking on the sidelines of the launch of the XC60 SUV model. Globally, Volvo does have plug-in hybrids in its portfolio, but Malhotra said the company will only consider launching them in India if the tax structures are more conducive. India currently levies a Goods and Services Tax (GST) rate of 5 per cent on EVs, and 43 per cent on hybrids. Overall, Malhotra said luxury car sales in India, which had been outpacing the broader car market in the last few years, slowed in the first half of 2025 as volatile stock markets, and mounting geopolitical tensions hit demand among the country's rich, aspirational buyers. He however added that Volvo is on track to meet its sales target for this calendar year though industry growth is likely to be muted. Per industry estimates, around 22,900 luxury cars were sold in the first half of 2025, a 1.8 per cent rise from a year earlier. Separately, Malhotra termed free trade agreements being inked or negotiated by the Indian government as a step in the right direction, which will help to grow the auto industry in the long run. 'The UK FTA has set a benchmark. While the one with the EU is still some time away, free trade agreements are good for the economy. India is seen as a market with growth potential. If any company were to invest in India today, they will only consider the scale available in the market here. With FTAs, the scale changes immediately as they open up access to many more markets globally,' he said, adding Volvo can also explore possibilities for expanding its footprint in India once the EU trade deal is finalised.
